News | March 04, 2021
COVAXIN demonstrates interim clinical efficacy of 81%
Bharat Biotech expects to share further details of the trial results as additional data become available.
Bharat Biotech expects to share further details of the trial results as additional data become available.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
ranules now has a total of 38 ANDA approvals from US FDA.
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
DHL and other logistics companies were already transporting pharmaceutical products at minus 70°C in Schaumaplast boxes packed with dry ice before the coronavirus pandemic
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
The jump in profit is due to the better performance of the API business.
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
Subscribe To Our Newsletter & Stay Updated
